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Breast cancer is the most prevalently diagnosed malignancy 
among women (Breast Cancer Care, 2019), with a new 
diagnosis being given every 10 minutes in the United 
Kingdom (Breast Cancer Care, 2018). While continuous 
improvements in the anti-cancer treatments offered for 
breast cancer have positively increased the number of 
women living into long-term survivorship (95.8% of women 
survive at least 1 year and 85.3% survive 5 years) (Office for 
National Statistics, 2019), research has shown that receiving 
a breast cancer diagnosis and undergoing a programme of 
active anti-cancer treatment induce a series of largely nega-
tive physical, psychological, emotional and cognitive short-
term and long-term side-effects or impairments (Bower, 
2008; Janelsins et al., 2011; Philip et al., 2013).
Interestingly, strong evidence has linked systemic chem-
otherapy treatment to cognitive dysfunction in around 16–
75 per cent of breast cancer survivors, a phenomenon 
commonly known as the ‘chemo-brain’ (Bower, 2008; 
Janelsins et al., 2014). In particular, survivors frequently 
reported experiencing difficulties in a range of cognitive 
domains including short- and long-term memory, executive 
function, attention, information processing and language 
production and/or comprehension (Cheung et al., 2012; 
Janelsins et al., 2011, 2014; Myers, 2013). Endocrine ther-
apy medications such as Tamoxifen and Aromatase 
Inhibitors (AI) have also been found to independently cause 
extensive levels of cognitive dysfunction (Bakoyiannis 
et al., 2016; Bender et al., 2015). Concerningly, researchers 
have identified that these impairments in cognitive func-
tions can persist for many years after the completion of 
anti-cancer treatment (Ahles et al., 2012; Koppelmans 
et al., 2012) significantly impairing quality of life (Klemp 
et al., 2018; Von Ah et al., 2009).
A majority of women following the diagnosis of breast 
cancer are at greater risk of developing depression, anxiety 
and post-traumatic stress disorder (PTSD) (Baqutayan, 2012; 
Jacob et al., 2016; Kenyon et al., 2014; Maass et al., 2015; 
Mehnert and Koch, 2007; Tsaras et al., 2018), which 
adversely impact quality of life and psychosocial well-being 
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(Akel et al., 2017; Dragomir et al., 2013; Saeedi-Saedi et al., 
2015) as well as the ability to function in everyday situations 
(i.e. working ability) (Adler and Page, 2008). It is critical that 
we develop a stronger understanding of the predictive power 
of the key risk factors (demographic factors, and perceived 
cognitive function) influencing emotional vulnerability, to 
aid the implementation of more targeted therapies for sus-
tained emotional resilience.
A considerable body of research has explored the effects 
of key breast cancer demographic factors (risk factors) in 
relation to women’s emotional health. For example, Van 
Londen et al. (2014) showed that breast cancer survivors 
actively receiving endocrine therapy medications (i.e. 
Tamoxifen) expressed higher levels of emotional distress, 
more potent worries about the possibility of cancer recur-
rence and greater upset regarding their appearance. Such 
negative emotional symptomologies are thought to be 
partly explained by the role of endocrine therapy medica-
tion on the natural production of oestrogen, noradrenaline 
and serotonin (5-HT) (Ito et al., 2006). Physical side effects 
including hot flushes, menopause, fatigue and thromboem-
bolic events (Kilickap et al., 2013; Syrowatka et al., 2017) 
are also likely to be linked to these heightened emotions. In 
addition, researchers have revealed that endocrine therapy 
medications significantly increase the severity of cognitive 
impairment experienced and lower women’s physical 
health–related quality of life (Ganz et al., 2016).
The grade of breast cancer diagnosed has only recently 
been investigated as a possible factor influencing quality of 
life of survivors. Despite long-standing evidence that a 
higher grade is associated with a greater chance of prema-
ture death (Elston and Ellis, 1991) and more intense anti-
cancer treatment(s), interestingly, Yang et al. (2017) 
identified higher grades (i.e. grade 2 (moderate) or 3 (high)) 
of cancer to be independently associated with a higher risk 
of experiencing emotional symptomologies including anxi-
ety and depression. One possible explanation is that women 
with high grades have more persistent ruminative thinking 
regarding cancer recurrence, metastasis and premature 
death. Considering that grade appears to have such a high 
emotional impact on breast cancer survivors, it is essential 
to address this factor in this study to ensure positive devel-
opments in the field and current interventions.
Furthermore, it has been reported that women diagnosed 
at a younger age exhibit a greater level of emotional dis-
tress (Gabriel and Domchek, 2010; Levkovich et al., 2018; 
Yang et al., 2017) during the post-treatment period com-
pared to older women. This has been associated with an 
acute long-term fear of developing secondary cancer and 
recurrence or metastasis of the original breast cancer (Wan 
et al., 2016; Ziner et al., 2012), as women diagnosed at a 
younger age often have more aggressive forms of cancer 
including invasive histopathology, greater node involve-
ment, high grade, larger tumour size, increased human epi-
dermal growth receptor 2 (HER2) and negative oestrogen 
receptors (Copson et al., 2013; Gajdos et al., 2000; 
Kheirelseid et al., 2011; Yazdani-Charati et al., 2019). 
Foreseeably, studies also delineated that worries regarding 
the symptoms of early menopause including hot flushes, 
night sweats and vaginal dryness (Rosenberg and Partridge, 
2013) as well as fertility incapacity, parenting responsibili-
ties, work duties and finance are highly powerful catalysts 
elevating emotional symptoms in young women diagnosed 
with breast cancer (Gabriel and Domchek, 2010; Ganz 
et al., 2003; Ruddy et al., 2013; Sharma and Purkayastha, 
2017; Wan et al., 2018).
It is clear from recent evidence that women experience 
the most severe levels of emotional vulnerability straight 
after the diagnosis and immediately after the completion of 
active anti-cancer treatment (Arving et al., 2007; Burgess 
et al., 2005; Henselmans et al., 2010). Although emotional 
stability progressively improves over time (Andersen et al., 
2017; Burgess et al., 2005), the risk of developing emo-
tional symptomologies including depression, anxiety and 
PTSD can remain atypically high for many years (Andersen 
et al., 2017; Bleiker et al., 2000).
While a substantial proportion of evidence has alluded 
to the existence of a noteworthy bidirectional relationship 
between the cognitive function and emotional well-being of 
breast cancer survivors (Von Ah et al., 2013; Von Ah and 
Tallman, 2015), only a scarce amount of research has exam-
ined this relationship systematically (Von Ah and Tallman, 
2015). Implementing the Functional Assessment of Cancer 
Therapy–Cognitive Scale (FACT-Cog) to assess 88 post-
treatment breast cancer survivors, Von Ah and Tallman 
(2015) revealed that perceived cognitive impairments, as 
well as perceived cognitive abilities, were significantly 
associated with the level of depression and anxiety experi-
enced supporting a strong interplay between perceived cog-
nitive function and the emotional disorders experienced by 
breast cancer survivors.
The concept that cognitive flexibility plays a determining 
role in maintaining a healthy emotional well-being has 
received increasing support from recent research that has 
successfully targeted cognitive dysfunction(s) using cogni-
tive control training (CCT) to boost emotional well-being in 
depression (Koster et al., 2017; Motter et al., 2016), as well 
as in subclinical anxiety and worry (Course-Choi et al., 2017; 
Sari et al., 2016). Accordingly, cognitive control has also 
been treated as a protective mechanism against emotional 
vulnerability impeding the progression of psychological dis-
tress to clinical psychopathology. Such research demon-
strates that CCT can be used to improve cognitive decline 
and, most importantly, depicts that the functions of cognition 
may protect against emotional vulnerability.
A recent training study conducted by Swainston and 
Derakshan (2018) revealed that breast cancer survivors 
who received 12 sessions of online dual n-back training 
experienced sustained improvements in emotional sympto-
mologies including rumination, anxiety and depression up 
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to 15 months after the completion of training. Previous 
research has also found cognitive memory and speed-pro-
cessing training among this population to result in improve-
ments of symptom distress and quality of life (Von Ah 
et al., 2012). While novel, these findings are highly perti-
nent given the high amount of psychological (or emotional) 
distress experienced pre-diagnosis, during and beyond anti-
cancer treatment.
The current study investigated the relationship between 
breast cancer survivor’s perceived cognitive function and 
their perceived emotional vulnerability and examined the 
predictive power and moderating role of four key demo-
graphic factors including (1) age at diagnosis, (2) time since 
diagnosis, (3) endocrine therapy status and (4) grade of 
breast cancer in this relationship, as well as in relation to the 
survivor’s quality of life. We elected to analyse these four 
particular demographic factors, as research has consistently 
pinpointed them to be highly salient influencers on breast 
cancer survivor’s emotional health and/or quality of life. 
Based on current research, we predicted that perceived cog-
nitive function would significantly relate to perceived emo-
tional vulnerability and quality of life. We also predicted that 
the four demographic (risk) factors would be associated with 
the severity of emotional vulnerability reported and moder-
ate the relationship between survivor’s perceived cognitive 
function and their perceived emotional vulnerability.
Method
Design
The design was cross-sectional. Participants were instructed 
to complete a battery of six online questionnaires on cogni-
tive and emotional health. The first variable we measured 
was the participant’s perceived cognitive function; this was 
measured at two levels through the execution of the FACT-
Cog and Perception of Cognition Questionnaire (PCQ). 
The second variable measured was the participant’s per-
ceived emotional well-being; we measured this on four lev-
els through the implementation of one mainstream 
questionnaire (Hospital Anxiety and Depression Scale 
(HADS)) and three cancer-specific questionnaires (Revised 
Impact of Events Scale (IES-R), Quality of Life 
Questionnaire (QoL) and Cancer Worry Scale (CWS)).
Participants
The participants recruited to partake in the present research 
were women (N = 132, mean age = 48.86, SD = 8.84; mean 
age at diagnosis = 45.58, SD = 8.41; mean number of months 
since diagnosis = 39.95, SD = 34.80) (one participant failed 
to specify their diagnosis as primary or secondary) who had 
previously received a clinical diagnosis of either primary 
(n = 119, mean age = 49.05, SD = 8.71; mean age at diagno-
sis = 46.08, SD = 8.21; mean number of months since 
diagnosis = 36.34, SD = 26.68) or secondary (n = 12, mean 
age = 47.08, SD = 10.60; mean age at secondary diagno-
sis = 40.67, SD = 9.57; mean number of months since diag-
nosis = 77.50, SD = 71.14) breast cancer.
Participants had to be in a post-active treatment phase 
not receiving anti-cancer treatment(s) including chemo-
therapy and/or radiotherapy. The participant could, how-
ever, be administering a regular hormone blocker therapy 
medication (i.e. Tamoxifen) or receiving target treat-
ments (i.e. Herceptin injection). Participants with a cur-
rent or former diagnosis of either a neurological or 
psychiatric condition (i.e. anxiety or depression) were 
eligible to take part.
Participants were recruited using voluntary sampling 
through online advertisements placed on social media plat-
forms including the ‘Building Resilience in Breast Cancer 
Centre’ (BRiC Centre; http://briccentre.bbk.ac.uk/). This 
research received ethical approval from the Research Ethics 
Committee of the Department of Psychological Sciences at 
Birkbeck College, University of London, and in accordance 
with the guidelines, all of our participants provided 
informed consent before completion of the study.
Materials
The General Demographics Questionnaire (GDQ). The 
29-item GDQ was developed to provide demographics 
such as the participants’ breast cancer diagnosis (i.e. pri-
mary or secondary breast cancer), clinical characteristics of 
their tumour (i.e. severity/grade of tumour, lymph node 
involvement, and hormone receptor status), and the pro-
gramme of active anti-cancer treatment they received (i.e. 
systemic chemotherapy and/or surgical). In addition, the 
GDQ also collects information relating to the general health 
habits (i.e. smoking, alcohol intake), neurological and psy-
chiatric medical history.
FACT-Cog. The FACT-Cog, Version 3 (Wagner et al., 2009) 
consists of 37 positively or negatively phrased items that 
evaluate participants’ subjective understanding of the treat-
ment-related changes in their cognitive function and the 
impact that these cognitive changes have had on their per-
ceived quality of life in the last 7 days. The items are sec-
tioned into four subscales (perceived cognitive impairments, 
comments from others, perceived cognitive abilities and 
impact on quality of life). Higher scores illustrate better 
cognitive function.
PCQ. The PCQ (Galantino et al., 2006) is a 7-item self-
report chemotherapy specific questionnaire that assesses 
the perceived changes in the cognitive function(s) of breast 
cancer patients following the completion of chemotherapy. 
The first six items known as the ‘perception of cognition’ 
measure the extent of cognitive change experienced, while 
the last item probes the general quality of life. Each item is 
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measured on a 7-point Likert-type scale with higher scores 
indicating better cognitive function.
The IES-R for cancer care. The IES-R is a standardised 
questionnaire by Horowitz et al. (1979) that can be modi-
fied for application in cancer care (Weiss, 2007; Weiss and 
Marmar, 1997). The modified IES-R consists of 22 tai-
lored items measuring cancer-related thoughts. It reflects 
the Diagnostic and Statistical Manual of Mental Disorders 
(4th ed.; DSM-IV) criteria for PTSD and assesses three key 
symptoms including avoidance, hyperarousal and intru-
sion. Individual’s responses are based on their own per-
sonal experience(s) with the symptoms over the last 7 days, 
with a higher combined score reflecting a greater PTSD 
symptom severity.
HADS. The HADS (Zigmond and Snaith, 1983) is a broadly 
used scale that measures levels of anxiety and depression 
among many clinical populations. It consists of 14 items: 7 
items relating to anxiety and 7 items relating to depression. 
Individual’s responses are based on the feelings (emotions) 
experienced over the past 7 days, with higher scores indi-
cating more chronic levels of depression and/or anxiety.
The QoL Short Version. The shortened QoL questionnaire 
(Ferrell et al., 1995) includes a 25-item, ordinal scale (rang-
ing from 0 to 10) measuring the quality of life of breast 
cancer patients. Subdivided into two scales known as 
‘physical health well-being’ (i.e. fatigue) and ‘psychologi-
cal well-being’ (i.e. life satisfaction), the QoL contains a 
series of questions addressing the individual’s experience(s) 
with distress throughout the illness and treatment period 
with higher scores representing better quality of life.
CWS. The CWS (derived from Custers et al.’s (2014) origi-
nal questionnaire) is an 8-item self-report questionnaire 
that measures the severity of fear for cancer recurrence and 
the impact that this fear has on the day-to-day functioning 
of individuals following treatment. Items are rated on a 
4-point Likert-type scale, with ‘1’ indicating ‘not at all or 
rarely’ and ‘4’ representing ‘almost all the time’. Higher 
scores indicate higher fear of cancer recurrence.
Procedure
Upon voluntary request, participants were emailed an 
information document outlining the primary purpose of the 
research as well as a secure web-address link (URL code) 
that re-directed them to the battery of self-report question-
naires. Before the study could commence, participants were 
presented with an online consent form. After the comple-
tion of this form, eligible participants were directed to fill 
in the 29-item GDQ regarding their personal breast cancer 
history followed by the two cognitive and four emotional 
well-being questionnaires.
Statistical analysis
A series of statistical analyses were performed using 
Statistical Package for the Social Sciences (SPSS, version 
24). Pearson’s correlation analyses were conducted between 
the two cognitive and four emotional well-being question-
naires to examine whether perceived cognitive function 
related to the emotional symptoms (vulnerability) (i.e. anx-
iety, depression, PTSD and cancer recurrence worry) and 
quality of life encountered by breast cancer survivors.
Two hierarchical regression analyses were performed: the 
first to examine the relationship between the breast cancer–
specific demographic factors (i.e. grade of breast cancer), 
perceived cognitive function and perceived emotional vul-
nerability (IES-R + HADS + CWS),1 and the second to 
investigate the influential factors on survivors’ perceived 
quality of life. In step 1 of our regression analyses, we 
included only the four selected demographic factors: (1) age 
at diagnosis, (2) time since diagnosis, (3) endocrine therapy 
status and (4) grade of breast cancer diagnosed. Measures of 
perceived cognitive function were then added in step 2.
Using analysis of standardised residual, we found no out-
liers in the data (emotional vulnerability: standard residual 
minimum = –2.35, standard residual maximum = 2.74; qual-
ity of life: standard residual minimum = –2.14, standard 
residual maximum = 2.87). Checks for violations of the 
assumptions of collinearity, independent error, normality, 
homoscedasticity and linearity were also conducted for each 
of the regression models using residuals (see Supplementary 
Material 1). In addition, post hoc analyses for achieved sta-
tistical power were conducted.
Finally, using moderation analyses, we investigated the 
moderating roles of the four aforementioned demograph-
ics on perceived cognitive function (as measured by the 
FACT-Cog questionnaire) in predicting perceived emo-
tional vulnerability (IES-R + HADS +CWS), as well as 
quality of life. Mean-centred values for perceived cogni-
tive function and quality of life were used. Checks for vio-
lations of the assumption of heteroscedasticity were also 
carried out, and all standard errors in the model were based 
on the Heteroscedasticity-Consistent Standard Error (HC3) 
estimator.
We decided to use the FACT-Cog total score in place of 
the four subscales for perceived cognitive function to 
increase power in our analyses.
Results
Of the 147 breast cancer survivors who originally volun-
teered to participate in our study, only two participants 
failed to meet the initial inclusion criteria (both were receiv-
ing active anti-cancer treatment). A further nine eligible par-
ticipants, however, failed to complete the seven 
questionnaires during a single session, and four participants 
withdrew from the study without providing a reason (see 
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Figure 1). Three additional participants were removed from 
the current regression analyses and three from the grade of 
breast cancer moderation analysis due to the incompleteness 
of the information they provided.
Correlation analysis
Perceived cognitive functioning as measured by the FACT-
Cog correlated negatively with the three emotional sympto-
mology questionnaires (IES-R, HADS and CWS). These 
results indicate that higher levels of impaired cognitive 
functioning were associated with higher levels of emotional 
vulnerability inclusive of experiencing worse cancer recur-
rence worries, anxiety, depression, and PTSD symptoms 
(see Table 1). Similarly, correlations were identified for the 
PCQ with the IES-R and HADS.
Predictably, our analyses also showed strong positive cor-
relations between the QoL questionnaire and both perceived 
cognitive function questionnaires (FACT-Cog and PCQ) 
suggesting that a higher perceived cognitive function is asso-
ciated with a better overall quality of life (see Table 1).
Regression analysis
Our first regression analysis (see Table 2) showed that the 
demographic factors in step 1 accounted for only a small 5 
per cent of the variance in emotional vulnerability. When 
FACT-Cog was entered at step 2, the second model explained 
26 per cent of the variance in emotional vulnerability signifi-
cantly, F(5, 123) = 8.77, p < .001. Of the four demographic 
factors included, only age at diagnosis exhibited a trend 
towards statistical significance (p = .12) in our final model, 
and FACT-Cog remained a significant predictor (p < .001). 
These results indicate that cognitive function predicts emo-
tional vulnerability above and beyond the four demographic 
factors, with lower levels of perceived cognitive function 
meeting higher levels of perceived emotional vulnerability.
Checks for violation of assumptions using residuals 
revealed that assumptions of collinearity (all tolerance > 0.1, 
variance inflation factor (VIF) < 10), independent errors 
(Durbin–Watson value = 1.83), normality and homogeneity 
of variance and linearity were all met for this regression 
model (see Supplementary Material 1). Moreover, post hoc 
analysis showed that this regression had a medium effect size 
(Cohen’s ƒ2 = 0.29) and an achieved statistical power of (1 – 
ß error probability) = 1.00.
Our second regression analysis investigating the quality 
of life (see Table 2) disclosed that the four demographics 
entered on step 1 accounted for a modest 8 per cent of the 
variance in women’s perceived quality of life.
FACT-Cog explained an extra 31 per cent of the vari-
ance at a significant level, F(5, 123) = 16.08, p < .001. 
Figure 1. Flowchart of the breast cancer survivor’s eligibility for the present study.
Table 1. Correlations between questionnaires measuring 
cognitive function and emotional vulnerability.
IES-R HADS QoL CWS FACT-Cog PCQ
IES-R 1 .65** –.56** .56** –.42** –.31**
HADS 1 –.71** .49** –.59** –.42**
QoL 1 –.56** .58** .34**
CWS 1 –.25** ns
FACT-Cog 1 .51**
PCQ 1
IES-R: Revised Impact of Events Scale; HADS: Hospital Anxiety and 
Depression Scale; QoL: Quality of Life Questionnaire; CWS: Cancer 
Worry Scale; FACT-Cog: Functional Assessment of Cancer Therapy–
Cognitive Scale; PCQ: Perception of Cognition Questionnaire.
**Correlation is significant at the .01 level (two-tailed).
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Importantly, both the grade of breast cancer diagnosed 
(p = .02) and the time since diagnosis (p = .02) as well as 
FACT-Cog (p < .001) functioned as significant predictors 
in the final model. These results show that perceived cogni-
tive function predicts overall quality of life above and 
beyond that of the four demographic factors included. 
Specifically, lower perceived function meets a poorer qual-
ity of life.
Checks for violation of assumptions using residuals 
showed that assumptions of collinearity (all tolerance > 0.1, 
VIF < 10), independent errors (Durbin–Watson value = 1.91), 
normality and homogeneity of variance and linearity were 
met in this regression model (see Supplementary Material 1). 
Post hoc analysis revealed that this regression analysis had a 
large effect size (Cohen’s ƒ2 = 0.52) and an achieved statistical 
power of (1 – ß error probability) = 1.00.
Moderation analysis
Our moderation analyses revealed that of the four moder-
ators assessed, grade of breast cancer diagnosed signifi-
cantly moderated the relationship between breast cancer 
survivor’s perceived cognitive function (as measured by 
the FACT-Cog) and their perceived emotional vulnerabil-
ity. The result indicated that approximately 32 per cent of 
the variation in the severity of emotional vulnerability 
reported could be explained by the main effects (grade of 
breast cancer and cognitive vulnerability) and the interac-
tion effects (grade of breast cancer × cognitive vulnera-
bility) (R2 = .32, F(5, 123) = 10.14, p < .001). The R2 
change due to the interaction was significant, p = .01. In 
addition, the analyses also revealed that none of the four 
demographic factors functioned as significant moderators 
in the relationship between perceived cognitive function 
and the quality of life of breast cancer survivors. All of the 
corresponding standard errors in the models were hetero-
scedasticity consistent, and thus, the assumption of heter-
oscedasticity was met.
The line chart of the simple slopes equations in Figure 2 
reveals the interaction between perceived cognitive func-
tion and emotional vulnerability moderated by grade such 
that strong negative relationships were found for grades 2 
(p = .04) and 3 (p < .001) (see Table 3) suggesting that the 
relationship between perceived cognitive function and 
Table 2. Hierarchical regression analyses for the predictors of emotional vulnerability and quality of life.
b SE B B t p
Emotional vulnerability
 Step 1
  Constant 2.41 [–0.62, 5.44] 1.53 1.57 .12
  Age at diagnosis –0.06 [–0.11, –0.00] 0.03 –.18 –2.03 .04
  Grade of breast cancer 0.27 [–0.37, 0.92] 0.33 .08 0.84 .40
  Endocrine therapies –0.38 [–1.39, 0.64] 0.51 –.07 –0.73 .46
  Time since diagnosis –0.00 [–0.02, 0.01] 0.01 –.02 –0.23 .82
 Step 2
  Constant 4.96 [2.15, 7.77] 1.42 3.49 .00
  Age at diagnosis –0.04 [–0.09, 0.01] 0.02 –.13 –1.56 .12
  Grade of breast cancer 0.15 [–0.42, 0.72] 0.29 .04 0.53 .60
  Endocrine therapies –0.39 [–1.29, 0.50] 0.45 –.07 –0.87 .39
  Time since diagnosis 0.00 [–0.01, 0.01] 0.01 .00 0.02 .98
  FACT-Cog Questionnaire –0.04 [–0.05, –0.02] 0.01 –.47 –5.97 .00
Quality of life
 Step 1
  Constant 117.95 [78.40, 157.50] 19.98 5.90 .00
  Age at diagnosis 0.52 [–0.18, 1.22] 0.35 .13 1.47 .15
  Grade of breast cancer –10.09 [–18.40, –1.71] 4.24 –.21 –2.38 .02
  Endocrine therapies 0.87 [–12.35, 14.09] 6.68 .01 0.13 .90
  Time since diagnosis –0.14 [–0.31, 0.04] 0.09 –.14 –1.57 .12
 Step 2
  Constant 77.04 [43.21, 110.86] 17.09 4.51 .00
  Age at diagnosis 0.24 [–0.33, 0.81] 0.29 .06 0.83 .41
  Grade of breast cancer –8.15 [–15.00, –1.29] 3.47 –.17 –2.35 .02
  Endocrine therapies 1.14 [–9.65, 11.92] 5.45 .02 0.21 .84
  Time since diagnosis –0.16 [–0.30, –0.02] 0.07 –.16 –2.29 .02
  FACT-Cog Questionnaire 0.59 [0.44, 0.73] 0.07 .57 7.96 .00
Emotional vulnerability: R2 = .049 for step 1, ∆R2 = .213 for step 2 (95% confidence intervals for B); quality of life: R2 = .083 for step 1, ∆R2 = .312 for 
step 2 (95% confidence intervals for B). FACT-Cog: Functional Assessment of Cancer Therapy–Cognitive Scale.
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perceived emotional vulnerability is significantly greater in 
breast cancer survivors diagnosed with higher (more 
severe) grades of cancer.
Discussion
This study investigated the relationship between perceived 
cognitive function and perceived emotional vulnerability 
and quality of life in breast cancer with a specific focus on 
demographic risk factors such as age at diagnosis, time 
since diagnosis, endocrine therapy status and grade of 
breast cancer.
As predicted, our results established a link between per-
ceived cognitive functioning and emotional vulnerability as 
well as quality of life. We found that age at diagnosis 
showed a trend towards being a significant predictor of 
emotional vulnerability, while both the grade of breast can-
cer and the time since diagnosis significantly predicted 
women’s perceived quality of life. Moreover, our modera-
tion analyses unveiled that women’s grade of breast cancer 
also significantly moderated the effects of cognitive func-
tion in predicting perceived emotional vulnerability.
Our findings on the link between cognitive function and 
emotional vulnerability extend on Von Ah and Tallman’s 
(2015) findings and imply that as a women’s confidence in 
their cognitive function improves and they become more able 
to live their daily life independently, the level to which they 
endure anxiety and/or depression symptomology decreases. 
Advancing the present body of literature, the results also 
showed perceived cognitive function to be associated with 
fears of cancer recurrence and PTSD symptomologies, emo-
tions that appear to have been mostly overlooked in previous 
cognitive breast cancer research. It is important to note, how-
ever, that our findings might have been influenced by the 
inclusion of breast cancer survivors with a current or previous 
diagnosis of depression (28%) or anxiety (5%). Considering 
the diverse range of symptoms associated with anxiety and 
depression (NHS, 2016a, 2016b), further qualitative research 
is required to develop a better understanding of the specific 
individual symptoms (i.e. irritability or feelings of hopeless-
ness) affected by cognitive function.
Imperatively, the results from the regression analysis fur-
ther revealed that breast cancer survivors’ perceived cogni-
tive function was the strongest predictor of their perceived 
level of emotional vulnerability, with grade of breast cancer 
significantly moderating this relationship. We found that a 
higher (more severe) grade resulted in a stronger relationship 
in which lower perceived cognitive function was coupled 
with a higher level of emotional vulnerability (see Figure 2). 
The present study is to our knowledge the first to establish 
the detrimental effect that grade of breast cancer has on the 
relationship between survivors’ cognitive and emotional 
health. Earlier research conducted by Yang et al. (2017) 
revealed that women with higher histological grades of inva-
sive breast cancer had a greater short-term risk of experienc-
ing anxiety and depression. Such findings are likely caused 
by higher levels of negative ruminative thinking about can-
cer recurrence, metastasis and premature death. Our findings 
highlight the need for professionals to consider women with 
higher breast cancer grade as more vulnerable and ensure 
that they are provided with adequate information as well as 
suitable emotional and cognitive (i.e. CCT) support to reduce 
the future risk of developing an affective disorder.
In line with previous research, age at the time of breast 
cancer diagnosis was found to show a strong trend for pre-
dicting emotional vulnerability in women, with a younger 
age inferring higher levels of emotional vulnerability. 
Notably, our results appear to largely support recent evi-
dence that women diagnosed at a younger age experience 
more intense emotional distresses (Gabriel and Domchek, 
2010; Levkovich et al., 2018; Yang et al., 2017) (such as 
anxiety and/or depression) elevating their overall level of 
vulnerability. One possible explanation for this finding is 
that younger women experience a more persistent and 
intense fear of cancer recurrence, metastasis and possible 
premature death (Wan et al., 2016; Ziner et al., 2012), as 
younger age at diagnosis is often associated with more 
Figure 2. Line chart of simple slope equations for the 
regression of predicted emotional vulnerability on perceived 
cognitive ability at three grades of breast cancer.
Table 3. Conditional effects for grade of breast cancer as a 
moderator of perceived emotional vulnerability.
Grade of 
breast cancer
b SE B t p
Grade 1 –0.01 [–0.06, 0.04] 0.03 –0.32 .75
Grade 2 –0.02 [–0.04, –0.00] 0.01 –2.10 .04
Grade 3 –0.06 [–0.08, –0.04] 0.01 –6.20 .00
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aggressive forms of cancer including high-grade tumours 
(Copson et al., 2013; Gajdos et al., 2000; Kheirelseid et al., 
2011; Yazdani-Charati et al., 2019). In addition, evidence 
has revealed that women diagnosed at a younger age expe-
rience more intense distress provoking factors including 
fear regarding the symptoms of early menopause (such as 
hot flushes, night sweats) (Rosenberg and Partridge, 2013), 
finance, fertility incapacity and parenting responsibilities 
(Gabriel and Domchek, 2010; Ganz et al., 2003; Ruddy 
et al., 2013; Wan et al., 2018), all of which are likely to 
prolong and enhance levels of emotional distress. Given the 
disabling effects that anxiety, depression, cancer recurrence 
worry and PTSD have on survivor’s psychosocial well-
being and their ability to function in everyday life (i.e. the 
ability to attend work) (Adler and Page, 2008; Saeedi-Saedi 
et al., 2015), this finding could positively direct the field of 
psycho-oncology to ensure that post-treatment support pro-
grammes are tailored to meet the survivor’s individual 
needs. For example, women diagnosed at a younger age 
should receive more frequent sessions of post-treatment 
support to aid a high level of emotional stability, which 
would, in turn, enable the maintenance of a more ‘typical’ 
daily routine.
Contradictory to past research, which has reported that 
the demographic factors such as endocrine therapy (Van 
Londen et al., 2014) and time since diagnosis (Arving et al., 
2007; Burgess et al., 2005; Henselmans et al., 2010) each 
has a strong effect on the severity of emotional vulnerabil-
ity endured by breast cancer survivors, this present study 
found no significant associations between these demo-
graphic (risk) factors and the level of emotional vulnerabil-
ity reported. It could be stipulated that no significant 
association was found with the effects of time on emotional 
vulnerability, as the vulnerability is at its highest in the 
immediate months following diagnosis and active anti-can-
cer treatment (Andersen et al., 2017; Burgess et al., 2005). 
Given that the mean time since diagnosis was 39.95 months 
for our study, this effect may have gone unnoticed. 
Similarly, approximately one-third of the recruited partici-
pants were not prescribed endocrine therapy medications 
such as Tamoxifen as part of their programme of treatment, 
medications which have been greatly associated with 
increased risk for developing emotional distress and cancer 
recurrence worry (Van Londen et al., 2014); this may have 
lowered our predictive power for this demographic factor. 
Due to the noteworthy disparity in our research, it would be 
highly valuable to further replicate this component of the 
study with a much larger participant sample.
Corresponding with previous research (Klemp et al., 
2018; Von Ah et al., 2009), we found that cognitive func-
tion was predictive of perceived quality of life. Specifically, 
the present study identified that women who outlined expe-
riencing less deterioration in their cognitive function con-
currently reported having a higher overall quality of life. 
Grade of breast cancer diagnosed was predictive of quality 
of life, with a higher grade (i.e. grades 2 or 3) resulting in a 
lower perceived quality of life. A likely explanation for this 
result is that women diagnosed with more severe grades of 
breast cancer endure a greater and more perpetual fear of 
breast cancer recurrence. They also receive higher doses of 
systemic chemotherapy and/or radiotherapy which induce 
inhibiting physical side effects such as alopecia and sleep 
disruption. The combination of recurrence fear and physi-
cal side effects could be directly responsible for women’s 
diminished ability to carry out their ‘normal’ daily activi-
ties such as socialising with friends or attending work.
Moreover, we identified time since diagnosis to be a pre-
dictive factor of survivor’s overall quality of life, with a 
longer period of time since diagnosis corresponding to a 
lower perceived quality of life. Conceivably, our study 
found this novel result as women with a longer time since 
their diagnosis are more likely to experience more intense 
ruminative thinking regarding the possibility of cancer 
recurrence. Women with a longer time since diagnosis are 
also more likely to have come to terms with the long-term 
detrimental effects that receiving a breast cancer diagnosis 
and undergoing anti-cancer treatment have on their life (i.e. 
long-term fatigue induced by treatment might cause social 
isolation). These findings are highly substantial, not only as 
they demonstrate predictive links but also as they reiterate 
the importance of acknowledging time since diagnosis, 
grade and their effects on breast cancer survivor’s overall 
well-being in future research.
As a collective, our findings have vital implications for 
researchers and health care services; in particular, they indi-
cate that further research should be carried out to explore the 
effects of CCT on the perceived cognitive function, emotional 
well-being and quality of life of younger breast cancer survi-
vors. As it stands currently, women with a breast cancer diag-
nosis are not routinely offered any form of CCT, despite 
strong evidence showing that it profoundly improves emo-
tional well-being (Course-Choi et al., 2017; Motter et al., 
2016; Sari et al., 2016; Swainston and Derakshan, 2018).
Research limitations and future directions for research. The 
present study displayed some methodological limitations 
that need to be taken into consideration when interpreting 
our results. A particular limitation within our study was that 
the questionnaires were only implemented at the one-time 
point, meaning that answers could have been influenced by 
mood or unusual events (i.e. cancer recurrence scare) that 
may have changed the participants’ current psychological 
state. Assessing trends of cognition and emotions through-
out the diagnosis, treatment trajectory and a few years post-
treatment would provide us with valuable data on patterns 
of perceived cognitive function and emotional vulnerability 
in breast cancer survivors. A second limitation is that we 
assumed that all of the women recruited had a sound under-
standing of the clinical characteristics of their breast cancer 
diagnosis (i.e. type and grade of tumour) and the treatment 
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received. Although clinical characteristics like grade are 
very well documented in patient’s official diagnostic (hos-
pital) letters and are focal during discussions with breast 
cancer clinicians, future research should conduct more 
individual checks (i.e. via interviews with clinicians or 
pathologist reports) to ensure that all the demographic 
information reported is correct. A final limitation of our 
study is that all of the participants were recruited using 
advertisements placed on social media platforms including 
Facebook and Twitter. As a consequence, our sample of 
women might not be representative of the much broader 
breast cancer population. In the future, researchers should, 
therefore, recruit survivors through a broader range of 
sources including patient oncology clinics.
Considering the current findings of our study, recom-
mendations for future research can be made. We suggest 
that this study is replicated on a much larger scale to pro-
vide a more in-depth account of younger breast cancer sur-
vivors’ cognitive and emotional health concerning specific 
demographic factors and moderator variables. In addition, 
future studies may wish to adopt a mixed methods approach 
incorporating qualitative, quantitative, and objective meas-
ures, as well as implementing longitudinal studies. This 
would provide a more thorough personal portrayal of breast 
cancer survivor’s experience and would also permit for 
assessing the long-term impact a breast cancer diagnosis 
and its treatment may have on survivor’s cognitive and 
emotional health. Finally, given the high association 
between cognition and emotional vulnerability in this sam-
ple, we advocate that future research and clinicians should 
further explore CCT in the breast cancer population to eval-
uate its effectiveness as this would aid the development of 
new interventions that primarily aim to improve emotional 
resilience in breast cancer survivors.
Conclusion
This study bestows crucial and novel findings that highlight 
the detrimental effects that perceived cognitive function, as 
well as various demographic (risk) factors, can have on 
breast cancer survivor’s emotional vulnerability and qual-
ity of life. Vitally, we established that perceived cognitive 
function significantly relates to the severity of emotional 
vulnerability endured by breast cancer survivors with grade 
of breast cancer moderating this relationship. Considering 
the shortfall of obtainable psychological interventions at an 
individual level, our findings are highly pertinent for clini-
cians and health care settings treating individuals with psy-
chological concerns as a repercussion of a breast cancer 
diagnosis and its treatment.
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Note
1. Based on the strong positive correlations identified between 
the Revised Impact of Events Scale (IES-R), Hospital Anxiety 
and Depression Scale (HADS) and Cancer Worry Scale (CWS) 
(all rs > .30, all p < .01), the standardised total scores achieved 
on these three questionnaires were combined for all subse-
quent analyses and are referred to as ‘emotional vulnerability’.
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